Get started
Work

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma

Year: 2016
Type: article
Abstract: Autologous hematopoietic cell transplant (HCT) is frequently used to treat plasma cell dyscrasias. High-dose melphalan is the most commonly utilized preparative regimen. Frequently seen non-hematologic adverse effects include oropharyngeal mucositis and GI toxicity. Reported incidence rate of overall and severe (grade 3-4) mucositis is 60-90% and 30-40%, respectively. Amifostine is a thiol derivative, which has been used for protection of normal tissues in radiation and chemotherapy. Amifostine has a relatively safe profile with hypotension, nausea, vomiting and diarrhea (N/V/D) as main side effects.
DOI: 10.1016/j.bbmt.2015.11.451
Authors: Vinita Gupta, Hulya Armutlugoynuk, Anant Vatsayan, Paolo Caimi, Brenda Cooper, Leland Metheny, Ehsan Malek, Stan L. Gerson, Erica Campagnaro, Marcos de Lima, Hillard M. Lazarus, Richard Creger
Institutions: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Şifa University, Case Western Reserve University, University Hospitals of Cleveland, U-M Rogel Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2508390735
FWCI:
Cites:
Cited by:
Related to: 10